Development of a Detection Method for Soluble Urokinase‐Type Plasminogen Activator Receptor and Its Application in Predicting Prognosis of Severe COVID‐19
Scandinavian Journal of Immunology · 2026-07 · 104 (1)
DOI: 10.1111/sji.70130 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scandinavian Journal of Immunology, online erschienen am 25.06.2026. Verfasst von Yulin Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, School of Public Health, Southern Medical University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: COVID-19, Receptors, Urokinase Plasminogen Activator. Die Arbeit nennt 29 Literaturangaben.
Abstract (Originalsprache)
Identifying sensitive and specific blood biomarkers for early warning of severe COVID‐19 remains a critical clinical need. Based on previous findings of elevated cytokines in bronchoalveolar lavage fluid and blood, we developed a novel luciferase immunosorbent assay (LISA) that selectively quantifies biologically active full‐length suPAR and can eliminate interference from inactive fragments measured by conventional ELISA. Compared with conventional ELISA, LISA showed a lower detection limit (5.08 vs. 45.72 pg/mL) and a wider linear range (45.72–100,000.00 vs. 1234.46–11,111.11 pg/mL). In adult COVID‐19 patients, suPAR levels were significantly elevated in severe cases ( p < 0.001) and correlated positively with NLR and SII ( p = 0.003 for each), and with IL‐6 ( p < 0.001), but negatively with lymphocyte count ( p = 0.004). suPAR outperformed conventional inflammatory markers in predicting severe disease (AUC = 0.785) and adverse outcomes (AUC = 0.912), supporting its role as an independent predictor. In paediatric COVID‐19 patients, suPAR remained superior to other single peripheral blood biomarkers for severity prediction, despite weaker correlations with inflammatory indices. This study establishes a reliable method for quantifying functionally intact suPAR and demonstrates its age‐dependent predictive value, highlighting its potential for individualized risk stratification in COVID‐19 patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology, School of Public Health, Southern Medical University, Guangzhou, Guangdong, China.
- Department of Clinical Microbiology, The First People's Hospital of Chenzhou, Chenzhou, Hunan, China.
- Institute of Global Health, Southern Medical University, Guangzhou, Guangdong, China.
- Dermatology Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Zitieren
APA
Yang, Y., Zhou, Z., Yuan, L., Chen, H., & Tang, S. (2026). Development of a Detection Method for Soluble Urokinase‐Type Plasminogen Activator Receptor and Its Application in Predicting Prognosis of Severe COVID‐19. Scandinavian Journal of Immunology, 104(1). https://doi.org/10.1111/sji.70130
Vancouver
Yang Y, Zhou Z, Yuan L, Chen H, Tang S. Development of a Detection Method for Soluble Urokinase‐Type Plasminogen Activator Receptor and Its Application in Predicting Prognosis of Severe COVID‐19. Scandinavian Journal of Immunology. 2026;104(1). doi:10.1111/sji.70130
BibTeX
@article{Yang2026,
author = {Yang, Yulin and Zhou, Zebin and Yuan, Liping and Chen, Hongliang and Tang, Shixing},
title = {Development of a Detection Method for Soluble Urokinase‐Type Plasminogen Activator Receptor and Its Application in Predicting Prognosis of Severe COVID‐19},
journal = {Scandinavian Journal of Immunology},
year = {2026},
volume = {104},
number = {1},
doi = {10.1111/sji.70130}
}
EUVIMED